PMID- 24459043
OWN - NLM
STAT- MEDLINE
DCOM- 20160606
LR  - 20150904
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 21
IP  - 7
DP  - 2015 Oct
TI  - Predicting Hyperhomocysteinemia by Methylenetetrahydrofolate Reductase C677T 
      Polymorphism in Chinese Patients With Hypertension.
PG  - 661-6
LID - 10.1177/1076029613519849 [doi]
AB  - OBJECTIVE: To evaluate the performance of methylenetetrahydrofolate reductase 
      (MTHFR) gene C677T polymorphism in predicting hyperhomocysteinemia (HHcy) in 
      Chinese patients with hypertension. METHODS: We measured plasma total 
      homocysteine tHcy level and C677T genotype in 1058 Chinese patients with 
      hypertension from 4 previous studies. We used 10, 15, and 20 mumol/L as cutoff 
      values for the definition of mild, modest, and severe HHcy, respectively. 
      Logistic models for HHcy were built from the study sample using the C677T 
      genotype as well as age and gender as predictors. The receiver-operating 
      characteristics of the models were evaluated. RESULTS: Our major findings are 
      that (1) C677T TT genotype is consistently associated with a higher tHcy across 
      the 4 studies, with an increase in size ranging from 38% to 68% in the 4 studies 
      and 51% overall. The C677T polymorphism independently explained about 14% of the 
      total variance of the normalized tHcy. (2) The TT genotype is associated with a 
      large increase in odds ratio (OR) for HHcy. Overall, the multivariate-adjusted 
      ORs for the TT genotype are 3.9 (95% confidence interval [CI]: 2.4-6.4), 6.5 (95% 
      CI: 4.0-10.6), and 17.9 (95% CI: 8.4-38.1) for mild, modest, and severe HHcy, 
      respectively. (3) Overall, the predicting performance increased with HHcy 
      severity, with sensitivity improving from 31.0% for mild HHcy to 70.3% for severe 
      HHcy, and with specificity slightly decreasing from 85.4% to 80.3%. Inclusion of 
      gender and age as predictors significantly improves the sensitivity, especially 
      for predicting mild HHcy. CONCLUSION: With an excellent sensitivity and a modest 
      specificity, C677T could be a useful screening marker for severe HHcy.
CI  - (c) The Author(s) 2014.
FAU - Wang, Yu
AU  - Wang Y
AD  - Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      P. R. China.
FAU - Xu, Xin
AU  - Xu X
AD  - Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      P. R. China.
FAU - Huo, Yong
AU  - Huo Y
AD  - Department of Cardiology, Peking University First Hospital and Medical 
      Department, Beijing, P. R. China.
FAU - Liu, Dahai
AU  - Liu D
AD  - School of Life Sciences, Anhui University, Hefei, P. R. China Center for Stem 
      Cell and Translational Medicine, School of Life Sciences, Anhui University, 
      Hefei, P. R. China.
FAU - Cui, Yimin
AU  - Cui Y
AD  - Department of Pharmacy, Peking University First Hospital and Medical Department, 
      Beijing, P. R. China.
FAU - Liu, Zeyuan
AU  - Liu Z
AD  - Department of Clinical Pharmacology, Affiliated Hospital, Academic of Military 
      Medical Sciences, Beijing, P. R. China.
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of pharmacy, Beijing Tiantan Hospital Affiliated to Capital Medical 
      University, Beijing, P. R. China.
FAU - Xu, Xiping
AU  - Xu X
AD  - Institute of Biomedicine, Anhui Medical University, Hefei, P. R. China.
FAU - Liu, Lisheng
AU  - Liu L
AD  - Beijing Fuwai Hospital, China Medical Academy, Beijing, P. R. China.
FAU - Li, Xiaoying
AU  - Li X
AD  - Department of Geriatric Cardiology, PLA General Hospital, Beijing, P. R. China.
FAU - Jiang, Shanqun
AU  - Jiang S
AD  - School of Life Sciences, Anhui University, Hefei, P. R. China Center for Stem 
      Cell and Translational Medicine, School of Life Sciences, Anhui University, 
      Hefei, P. R. China Institute of Biomedicine, Anhui Medical University, Hefei, P. 
      R. China shanqun@gmail.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140122
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Homocysteine/blood
MH  - Humans
MH  - Hyperhomocysteinemia/*enzymology/*genetics
MH  - Hypertension/*enzymology/*genetics
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
MH  - Middle Aged
MH  - *Polymorphism, Genetic
OTO - NOTNLM
OT  - MTHFR
OT  - hyperhomocysteinemia
OT  - hypertension
OT  - polymorphism
OT  - prediction
EDAT- 2014/01/25 06:00
MHDA- 2016/06/09 06:00
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2016/06/09 06:00 [medline]
AID - 1076029613519849 [pii]
AID - 10.1177/1076029613519849 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2015 Oct;21(7):661-6. doi: 10.1177/1076029613519849. 
      Epub 2014 Jan 22.